share_log

TECON BIOLOGYLTD (SZSE:002100 Investor Three-year Losses Grow to 11% as the Stock Sheds CN¥478m This Past Week

TECON BIOLOGYLTD (SZSE:002100 Investor Three-year Losses Grow to 11% as the Stock Sheds CN¥478m This Past Week

TECON生物技術股份有限公司(SZSE:002100)投資者三年損失增至11%,本週該股票脫落了4.78億元人民幣。
Simply Wall St ·  06/10 18:38

It can certainly be frustrating when a stock does not perform as hoped. But it can difficult to make money in a declining market. While the TECON BIOLOGY Co.LTD (SZSE:002100) share price is down 13% in the last three years, the total return to shareholders (which includes dividends) was -11%. That's better than the market which declined 23% over the last three years.

當一隻股票的走勢不符合預期時,確實會讓人感到沮喪。但在一個下跌的市場裏賺錢可能並不容易。儘管天康生物股份有限公司(SZSE:002100)的股價在過去三年中下跌了13%,但股東的總回報(其中包括股息)爲-11%。這比市場的跌幅23%好一些。

If the past week is anything to go by, investor sentiment for TECON BIOLOGYLTD isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果過去一週是真的,那麼天康生物股份有限公司的投資者情緒並不是很樂觀,因此讓我們來看看基本面和股價之間是否存在不匹配問題。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

雖然一些人仍然在教授高效市場假說,但已經證明市場是過度反應的動態系統,投資者不總是理性的。一種有缺陷但合理的評估公司情緒變化的方法是比較每股收益 (EPS) 與股價。

TECON BIOLOGYLTD saw its share price decline over the three years in which its EPS also dropped, falling to a loss. Since the company has fallen to a loss making position, it's hard to compare the change in EPS with the share price change. However, we can say we'd expect to see a falling share price in this scenario.

天康生物股份有限公司的股價在過去三年中下跌,其每股收益也下降至虧損。由於該公司轉入了虧損地帶,因此很難將每股收益的變化與股價的變化進行比較。然而,在這種情況下,我們可以肯定地說,股價應該會下跌。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下面的圖片中查看每股收益如何隨時間變化(單擊圖表以查看確切的價值)。

earnings-per-share-growth
SZSE:002100 Earnings Per Share Growth June 10th 2024
SZSE:002100每股收益增長2024年6月10日

It might be well worthwhile taking a look at our free report on TECON BIOLOGYLTD's earnings, revenue and cash flow.

我們已經介紹了天康生物股份有限公司的股價表現,但我們也應該提到其股東總回報(TSR)。 TSR試圖捕捉股息的價值(就像它們已被再投資一樣),以及公司向股東提供的任何剝離或折價的資本增發。天康生物股份有限公司的TSR在過去的三年中損失了11%。儘管它支付了股息,但它的股價回報並不那麼糟糕。

What About The Total Shareholder Return (TSR)?

那麼,股東總回報(TSR)呢?

We've already covered TECON BIOLOGYLTD's share price action, but we should also mention its total shareholder return (TSR). The TSR attempts to capture the value of dividends (as if they were reinvested) as well as any spin-offs or discounted capital raisings offered to shareholders. TECON BIOLOGYLTD's TSR of was a loss of 11% for the 3 years. That wasn't as bad as its share price return, because it has paid dividends.

可能值得一看的是我們關於天康生物股份有限公司收益、營業收入和現金流的免費報告。我們已經介紹了天康生物股份有限公司的股價表現,但我們也應該提到其股東總回報(TSR)。 TSR試圖捕捉股息的價值(就像它們已被再投資一樣),以及公司向股東提供的任何剝離或折價的資本增發。天康生物股份有限公司的TSR在過去的三年中損失了11%。儘管它支付了股息,但它的股價回報並不那麼糟糕。

A Different Perspective

不同的觀點

Although it hurts that TECON BIOLOGYLTD returned a loss of 0.7% in the last twelve months, the broader market was actually worse, returning a loss of 12%. Longer term investors wouldn't be so upset, since they would have made 1.3%, each year, over five years. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 1 warning sign for TECON BIOLOGYLTD that you should be aware of.

雖然天康生物股份有限公司在過去的十二個月中損失了0.7%,但更廣泛的市場實際上表現更差,損失了12%。從長期來看,投資者不會那麼沮喪,因爲他們每年可以獲得1.3%的回報,持有五年的話。最好的情況是過去一年只是征程中的短暫波動。我認爲長期股價變化是企業績效的一種代理,但要真正獲得洞察力,我們還需要考慮其他信息。例如,我們已經發現天康生物股份有限公司存在1個警示信號,您應該注意。

For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket.

對於那些喜歡尋找獲勝投資的人來說,最近有內部購買的低估公司免費列表可能是一個很好的選擇。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論